Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Neovascularisation or Macular Edema
NCT03211741Phase 4Completed
- Sponsor
- Ghent University Hospital
- Start
- Nov 2013
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of bevacizumab in Retinal neovascularization, macular edema, sponsored by Ghent University Hospital. Started Nov 2013; status: completed.
02
Drugs
bevacizumab
03
Conditions
Retinal neovascularizationmacular edema
Beyond the preview
Go deeper on NCT03211741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03211741.